Phase 3 efficacy and safety of the ELX/TEZ/ iva triple combination in people with CF and F508del/minimal function genotypes - Jain, R; Mall, M; Dřevínek, P (North American Cystic Fibrosis Conference)
TN 2019; Poster 507